Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Hydromorphone vs Oxycodone CR in Cancer Pain
NCT01205126Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in cancer pain (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire at Day 29. Started Dec 2009; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01205126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205126.